Reproducibility and utility of an overnight 0.25  mg @entity619 suppression test as a marker for glucocorticoid sensitivity in XXXX with @entity565 .

@entity1 @entity12131 @entity565 @entity5482 @entity619 @entity4185 @entity701
PURPOSE: @entity4185 ( @entity4185 ) are the cornerstone of @entity565 treatment in @entity1 . However, there is considerable inter-individual variation in glucocorticoid sensitivity, leading to over- as well as undertreatment. A simple and fast test to predict glucocorticoid sensitivity would enable more tailored therapy in @entity1 with @entity565 . AIM: To study reproducibility and utility of an overnight 0.25  mg @entity619 suppression test (DST) with salivary @entity701 levels as marker for glucocorticoid sensitivity in asthmatic @entity1 . METHODS: 23 @entity1 with @entity12131 were recruited for two overnight 0.25  mg DST's, 1  month apart. RESULTS: Baseline @entity701 levels correlated well between both tests. However, @entity701 levels, change in @entity701 levels or fractional suppression of @entity701 levels after @entity619 did not correlate between the two tests. Bland-Altman plots showed that the difference in salivary @entity701 levels between @entity5482 of an individual @entity1 could go up to 12  nmol/l, which is a clinically relevant difference. @entity4185 dose did not correlate with baseline @entity701 levels, height and BMI SDS. CONCLUSION: The low-dose salivary DST test in its current form is not suitable for use in clinical practice in @entity1 with @entity565 , due to low reproducibility. Therefore, studies using the 0.25  mg salivary DST should be interpreted cautiously.
